{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:58:41Z","timestamp":1740135521728,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Variability in triazole plasma concentrations by drug interactions is well known. An interaction between voriconazole and flucloxacillin has already been described. In our case we observed a similar interaction between posaconazole and flucloxacillin, which in our knowledge has not ever been reported in literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 60-year-old male who had a double lung transplantation for end-stage chronic obstructive pulmonary disease was being treated with voriconazole for invasive pulmonary aspergillosis (IPA). During this treatment he presented at the emergency room and was diagnosed with endocarditis for which a combination of amoxicillin, flucloxacillin and gentamicin was initiated. A known interaction between voriconazole and flucloxacillin was observed, with a drop of the voriconazole levels, and treatment for IPA was switched to posaconazole. After ending the treatment for endocarditis, the patient had a catheter infection for which flucloxacillin was reinitiated. Unexpectedly we saw a similar immediate drop in posaconazole levels, recovering after ending treatment with flucloxacillin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We describe a new interaction between posaconazole and flucloxacillin. Presumably the underlying mechanism is activation of the pregnane X receptor by flucloxacillin, which can induce cytochrome P450, uridine glucuronosyl transferase (UGT1A4) and P-glycoprotein. We advise caution when combining flucloxacillin and triazoles, because interactions may lead to undertreatment of invasive aspergillosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-01904-4","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T12:08:44Z","timestamp":1648469324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report"],"prefix":"10.1186","volume":"22","author":[{"given":"Saartje","family":"Verfaillie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Godinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Vos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3048-2429","authenticated-orcid":false,"given":"Geert M.","family":"Verleden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,27]]},"reference":[{"issue":"1","key":"1904_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-017-0235-8","volume":"16","author":"WM Yi","year":"2017","unstructured":"Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017;16(1):1\u201314.","journal-title":"Ann Clin Microbiol Antimicrob."},{"issue":"10273","key":"1904_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","volume":"397","author":"JA Maertens","year":"2021","unstructured":"Maertens JA, Rahav G, Lee D-G, Ponce-de-Le\u00f3n A, Ram\u00edrez S\u00e1nchez IC, Klimko N, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499\u2013509.","journal-title":"Lancet."},{"issue":"3","key":"1904_CR3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/cid\/ciaa652","volume":"73","author":"P Samanta","year":"2021","unstructured":"Samanta P, Clancy CJ, Marini RV, Rivosecchi RM, McCreary EK, Shields RK, et al. Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients. Clin Infect Dis. 2021;73(3):416\u201326.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"1904_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jof7020076","volume":"7","author":"ME Klatt","year":"2021","unstructured":"Klatt ME, Eschenauer GA. Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. J Fungi. 2021;7(2):1\u201316.","journal-title":"J Fungi."},{"issue":"2","key":"1904_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/dmd.32.2.267","volume":"32","author":"A Ghosal","year":"2004","unstructured":"Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos. 2004;32(2):267\u201371.","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"1904_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","volume":"16","author":"R Van Daele","year":"2020","unstructured":"Van Daele R, Spriet I, Maertens J. Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. Expert Opin Drug Metab Toxicol. 2020;16(7):539\u201350.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"11","key":"1904_CR7","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00228-013-1552-2","volume":"69","author":"QQ Du","year":"2013","unstructured":"Du QQ, Wang ZJ, He L, Jiang XH, Wang L. PXR polymorphisms and their impact on pharmacokinetics\/pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013;69(11):1917\u201325.","journal-title":"Eur J Clin Pharmacol."},{"issue":"7","key":"1904_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/jac\/dkv069","volume":"70","author":"B Kennedy","year":"2015","unstructured":"Kennedy B, Larcombe R, Chaptini C, Gordon DL. Interaction between voriconazole and flucloxacillin during treatment of disseminated Scedosporium apiospermum infection. J Antimicrob Chemother. 2015;70(7):2171\u20133.","journal-title":"J Antimicrob Chemother."},{"issue":"9","key":"1904_CR9","doi-asserted-by":"publisher","first-page":"e00915","DOI":"10.1128\/AAC.00915-17","volume":"61","author":"EW Muilwijk","year":"2017","unstructured":"Muilwijk EW, Dekkers BGJ, Henriet SSV, Verweij PE, Witjes B, Oude Lashof AML, et al. Flucloxacillin results in suboptimal plasma voriconazole concentrations. Antimicrob Agents Chemother. 2017;61(9):e00915-17.","journal-title":"Antimicrob Agents Chemother."},{"unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019;1\u201310.","key":"1904_CR10"},{"doi-asserted-by":"crossref","unstructured":"Yao N, Zeng C, Zhan T, He F, Liu M, Liu F, et al. Oleanolic acid and ursolic acid induce UGT1A1 expression in HepG2 cells by activating PXR rather than CAR. Front Pharmacol. 2019;10(SEP).","key":"1904_CR11","DOI":"10.3389\/fphar.2019.01111"},{"doi-asserted-by":"crossref","unstructured":"Chawke LJ, Hunt EB, Kennedy MP, Murphy DM. Post-tuberculosis mycetoma: Bronchoscopic removal. Respirol Case Reports. 2017;5(4):e00243.","key":"1904_CR12","DOI":"10.1002\/rcr2.243"},{"issue":"8","key":"1904_CR13","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1124\/dmd.108.020701","volume":"36","author":"K Yasuda","year":"2008","unstructured":"Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, et al. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008;36(8):1689\u201397.","journal-title":"Drug Metab Dispos."}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-01904-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-01904-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T12:08:56Z","timestamp":1648469336000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-01904-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,27]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1904"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-01904-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"type":"electronic","value":"1471-2466"}],"subject":[],"published":{"date-parts":[[2022,3,27]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient had the chance to read the article and written informed consent to publish the above-mentioned information was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}